Market Research Center has published a report analyzing the global cell and gene therapy CDMO market from 2026 to 2032. The market was worth approximately US$5.067 billion in 2025 and is projected to reach approximately US$18.53 billion by 2032, representing a CAGR of 20.7%.
The report presents an analysis of the global cell and gene therapy CDMO market, including market size, trends and segment-based forecasts. The cell and gene therapy CDMO market is expected to grow from its 2025 baseline between 2026 and 2032. Trends and segmentation by major region are organized to provide insight into providers' portfolios, market shares and future developments. The report introduces segment analysis by type (cell therapy and gene therapy) and application (clinical and commercial stages), and discusses changes in market size by region and initiatives by major companies.
Major global companies cited include Lonza Pharmaceuticals, Thermo Fisher, Catalent, Jubilant Life Sciences and Boehringer Ingelheim. The report expects the companies with the largest revenue shares as of 2025 to drive the market. It provides forecasts by region, type and application, and summarizes the factors and risks expected to support future market trends, along with the competitive landscape.